Moderna takes one more step along the high-wire act of Covid-19 vaccine work, offering markers of success for the most vulnerable age group
One of the big questions facing any of the Covid-19 vaccines is whether or not they can protect the elderly — the most vulnerable group facing a potentially lethal virus.
We don’t know yet how that will play out in event-driven Phase IIIs with 30,000 patients, but Moderna $MRNA today just offered up a safety and efficacy profile for their vaccine in an early-stage test that provides some clear biomarker data backing up mRNA-1273 across the spectrum of age groups now under the microscope. And that takes them one step closer to potentially fielding a new vaccine for what could pan out as a global, $20 billion market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.